Literature DB >> 17312045

Practical approach to diagnostic CT combined with PET.

Terence Z Wong1, Erik K Paulson, Rendon C Nelson, Edward F Patz, R Edward Coleman.   

Abstract

OBJECTIVE: Protocols for PET/CT are not yet standardized. In particular, image quality, utilization, and reporting of the findings of the CT component of PET/CT can vary widely, making it complicated for physicians to request the appropriate information. In an effort to address this problem, we describe a set of four PET/CT protocols that satisfy a broad range of clinical needs among oncology patients. Current technology allows acquisition of diagnostic-quality CT scans as part of PET/CT examinations, and referring physicians are given the option of requesting formal interpretation of the CT findings. In this case, the PET and CT images are interpreted by the corresponding specialists, and equivocal or discordant findings are adjudicated through joint review of the PET/CT images.
CONCLUSIONS: The menu of PET/CT imaging protocols has gained wide acceptance by our referring physicians and have been used successfully in more than 6,000 PET/CT studies. Newer PET/CT protocols will be developed as technology advances. Continued collaboration among oncologists, CT specialists, and nuclear medicine specialists is essential for deriving the maximum clinical benefit from combined PET/CT. Standardization of imaging protocols will become increasingly important as multiple-institution trials are developed for evaluation of present and future applications of PET/CT.

Entities:  

Mesh:

Year:  2007        PMID: 17312045     DOI: 10.2214/AJR.06.0813

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  8 in total

1.  Multiphase contrast-enhanced CT with highly concentrated contrast agent can be used for PET attenuation correction in integrated PET/CT imaging.

Authors:  Philip Aschoff; Christian Plathow; Thomas Beyer; Matthias P Lichy; Gunter Erb; Mehmet Ö Öksüz; Claus D Claussen; Christina Pfannenberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-29       Impact factor: 9.236

2.  Positron Emission Tomography (PET) in Oncology: A Systematic Review of Clinical Effectiveness and Indications for Use.

Authors: 
Journal:  CADTH Technol Overv       Date:  2010-12-01

3.  A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma.

Authors:  Georgia M Beasley; Colin Parsons; Gloria Broadwater; M Angelica Selim; Suroosh Marzban; Amy P Abernethy; April K S Salama; Edward A Eikman; Terence Wong; Jonathan S Zager; Douglas S Tyler
Journal:  Ann Surg       Date:  2012-08       Impact factor: 12.969

4.  Fluorodeoxyglucose-positron-emission tomography imaging of head and neck squamous cell cancer.

Authors:  R M Subramaniam; M Truong; P Peller; O Sakai; G Mercier
Journal:  AJNR Am J Neuroradiol       Date:  2009-11-12       Impact factor: 3.825

5.  Integrated FDG PET/CT: Utility and Applications in Clinical Oncology.

Authors:  Inmaculada Pinilla; Beatriz Rodríguez-Vigil; Nieves Gómez-León
Journal:  Clin Med Oncol       Date:  2008-09-19

6.  A Deep Learning Model to Automate Skeletal Muscle Area Measurement on Computed Tomography Images.

Authors:  Kaushalya C Amarasinghe; Jamie Lopes; Julian Beraldo; Nicole Kiss; Nicholas Bucknell; Sarah Everitt; Price Jackson; Cassandra Litchfield; Linda Denehy; Benjamin J Blyth; Shankar Siva; Michael MacManus; David Ball; Jason Li; Nicholas Hardcastle
Journal:  Front Oncol       Date:  2021-05-07       Impact factor: 6.244

7.  PET/CT: Current status in India.

Authors:  Venkatesh Rangarajan; Nilendu C Purandare; Anshu R Sharma; Sneha Shah
Journal:  Indian J Radiol Imaging       Date:  2008-11

Review 8.  How we read pediatric PET/CT: indications and strategies for image acquisition, interpretation and reporting.

Authors:  Gabrielle C Colleran; Neha Kwatra; Leah Oberg; Frederick D Grant; Laura Drubach; Michael J Callahan; Robert D MacDougall; Frederic H Fahey; Stephan D Voss
Journal:  Cancer Imaging       Date:  2017-11-07       Impact factor: 3.909

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.